FDA approves Lynparza as maintenance treatment with bevacizumab for HRD-positive ovarian cancer
AstraZeneca and Merck & Co have received the FDA’s approval for Lynparza (olaparib) as 1st-line maintenance treatment with bevacizumab for
Read moreAstraZeneca and Merck & Co have received the FDA’s approval for Lynparza (olaparib) as 1st-line maintenance treatment with bevacizumab for
Read moreScientists at clinical-stage biopharmaceutical company Harbour BioMed (HBM), Utrecht University and Erasmus Medical Center announced that they have discovered a
Read moreSwiss pharma giant Roche has received Emergency Use Authorisation (EUA) from the FDA for its latest COVID-19 antibody test –
Read moreNew post-hoc analysis of six years of study data for Roche’s OCREVUS (ocrelizumab) shows earlier treatment initiation nearly halves the
Read moreThe U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for emergency use of Gilead’s remdesivir
Read moreModerna, a clinical-stage biotech developing messenger RNA (mRNA) therapeutics and vaccines, and Swiss pharma giant Lonza today announced the introduction
Read moreUK-headquartered AstraZeneca and Oxford University announced an agreement to develop and distribute the university’s future recombinant adenovirus vaccine to prevent
Read moreJapanese research-driven pharmaceutical company Shionogi & Co., Ltd. and its European subsidiary, Shionogi B.V. announced on April 28 that the
Read moreRemdesivir, an investigational nucleotide analog with broad-spectrum antiviral activity developed by the Californian biopharmaceutical company Gilead Sciences, has shown promising
Read moreNubilaria is providing it’s innovative ACTide EDC system free in support of a clinical study for COVID-19 related ARDS intensive
Read more